At 30.3x earnings with a Forward P/E of 8.1 and a PEG Forward of 0.5, this stock screens as a classic GARP mispricing. The market is valuing current earnings expensively while simultaneously discounting next year’s growth trajectory, creating a sharp valuation disconnect. An Altman Z-Score of 5.3 and a Current Ratio of 5.2 signal exceptional balance sheet safety with minimal bankruptcy risk, while Debt/Equity of just 12.70% reinforces financial stability. This is not a distressed biotech — it is a fundamentally solvent, institutionally owned ($89.22) company trading at what appears to be a compressed forward multiple relative to growth expectations.
As a Biotechnology company within Healthcare, BioMarin operates in a data-intensive, research-driven field that stands to benefit materially from AI-driven drug discovery and clinical modeling. AI integration can accelerate pipeline productivity and improve R&D efficiency, which is critical in a margin-sensitive business with a 5.70% operating margin. Companies that harness computational biology effectively can expand ROIC beyond the current 4.70% baseline.
From a GARP lens, the Forward P/E of 8.1 combined with a PEG of 0.5 is the central attraction — you are paying a single-digit multiple for forward earnings with growth priced at a discount. Return on Equity of 16.90% demonstrates the business can compound shareholder capital at respectable rates, while the Piotroski F-Score of 5 indicates stable, if not elite, financial health. Operating Margin of 5.70% leaves room for operating leverage if revenue scales, and with Market Cap at $10,487M, the company is large enough to access capital markets efficiently but small enough to rerate. The Altman Z-Score of 5.3 removes solvency concerns, which is rare in biotech. This is the type of setup institutions accumulate before earnings inflect.
Now the problems. Operating Margin at 5.70% and ROIC at 4.70% are not impressive for a company trading at 30.3x trailing earnings — execution must improve materially to justify historical valuation. The Piotroski F-Score of 5 is merely average, not signaling strong operational momentum. EPS is listed at 16.6 while EPS Next Year is estimated at $1.82, a dramatic implied normalization that raises quality-of-earnings questions. With no meaningful dividend (0.1 TTM Yield and 0 five-year average), investors rely entirely on execution and multiple expansion, leaving no income cushion if growth stalls.
United States
BioMarin is a commercial-stage biotechnology company focused on developing and marketing therapies for rare and ultra-rare genetic diseases. Its moat is built on intellectual property, regulatory exclusivity, and high switching costs once therapies become standard of care. Revenue is generated through specialized therapeutics that command premium pricing due to limited competition and high unmet medical need. The combination of orphan drug positioning, patent protection, and deep scientific expertise creates durable cash flow streams once products reach commercialization.
